Sisomicin

Sisomicin is an aminoglycoside antibiotic that is used in the treatment of various types of bacterial infections. It was first isolated in 1973 from the fermentation broth of Micromonospora inyoensis, a species of actinobacteria.

History[edit | edit source]

Sisomicin was discovered in 1973 by researchers at the Schering Corporation. It was found to be produced by Micromonospora inyoensis, a species of actinobacteria that was isolated from a soil sample collected in Inyo County, California. The antibiotic was named after the genus Sisomicin of the bacteria from which it was derived.

Mechanism of Action[edit | edit source]

Like other aminoglycoside antibiotics, sisomicin works by binding to the 30S ribosomal subunit of the bacterial ribosome, thereby inhibiting protein synthesis. This results in the death of the bacterial cells, effectively treating the infection.

Medical Uses[edit | edit source]

Sisomicin is used to treat a variety of bacterial infections, including those caused by Gram-negative bacteria such as Pseudomonas aeruginosa, Escherichia coli, and Klebsiella pneumoniae. It is also effective against some Gram-positive bacteria, including certain strains of Staphylococcus aureus and Streptococcus pneumoniae.

Side Effects[edit | edit source]

As with other aminoglycoside antibiotics, the use of sisomicin can lead to several side effects. These include ototoxicity, which can result in hearing loss or balance problems, and nephrotoxicity, which can cause kidney damage. Other potential side effects include allergic reactions and blood disorders.